Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.37 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KIF11 | P52732 | 6/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24783495 | 0.93 | CYP11B1 (0.47) | SMYD3TP53CYP11B1CYP11B2XIAP | |
| SCHEMBL11455059 | 0.77 | EPHX2 (0.51) | SMYD3TP53CYP11B1CYP11B2RAF1 | |
| SCHEMBL30509208 | 0.77 | EPHX2 (0.51) | SMYD3TP53CYP11B1CYP11B2RAF1 | |
| SCHEMBL23432583 | 0.76 | CYP11B1 (0.43) | SMYD3TP53CYP11B1CYP11B2XIAP | |
| SCHEMBL23346087 | 0.75 | — | — | |
| SCHEMBL22278373 | 0.74 | CMA1 (0.56) | SMYD3CYP11B1CYP11B2 | |
| SCHEMBL12361998 | 0.74 | AHR (0.56) | SMYD3CYP11B1CYP11B2MAPTKIF11 | |
| SCHEMBL15521357 | 0.74 | AHR (0.56) | SMYD3KIF11CRBNPKM | |
| SCHEMBL11463464 | 0.73 | AHR (0.55) | SMYD3TP53CYP11B1CYP11B2RAF1 | |
| SCHEMBL3594659 | 0.73 | CA9 (0.53) | SMYD3TP53CYP11B1CYP11B2RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010038803-A1 | 2-INDOLEACRYLAMIDE ANALOGUE | 持田製薬株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | SMYD3 236/4885TP53 3619/4885CYP11B1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.